ABSTRACT The pathogenicity offixed rabies virus strains for adult mice depends on the presence of an antigenic determinant on the viral glycoprotein. Two virus-neutralizing monoclonal antibodies have been used to identify this determinant. All pathogenic strains of fixed rabies virus bind to these antibodies and are neutralized by them, whereas nonpathogenic strains fail to react with these monoclonal antibodies and are not neutralized by them. Antigenic variants of the rabies virus with altered glycoprotein were selected by growing virus in the presence of one monoclonal antibody, 194-2. All variants that lost their ability to react with this antibody and an additional antibody, 248-8, were found to be nonpathogenic for adult mice. Analysis of tryptic peptides of the glycoproteins of pathogenic parent virus and nonpathogenic 'variants and the amino acid sequence of a specific variant tryptic peptide revealed that the change in pathogenicity corresponded to an amino acid substitution at position 333 of the glycoprotein molecule. The nucleotide sequence of the nonpathogenic variant glycoprotein gene contained a base change that confirmed the single amino acid substitution in the tryptic peptide replacing arginine-333 in the parental glycoprotein. We conclude that arginine-333 is essential for the integrity of an antigenic determinant and for the ability of rabies viruses to produce lethal infection in adult mice.
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Fixed rabies virus strains differ greatly in their lethality for adult mice, and the factors governing the regulation of rabies virus pathogenicity appear to be diverse and variable, depending on virus growth conditions and virus strain (1) (2) (3) (4) . In other virus systems, the virion structural proteins have been identified as determinants in pathogenicity. The hemagglutinin (HA) surface glycoprotein appears to play a critical role in the neurovirulence of influenza virus (5, 6) , although other proteins derived from an "optimum" viral gene constellation may influence the pathogenicity ofinfluenza viruses (7, 8) . Similarly, the surface hemagglutinin (HN) and fusion (F) glycoproteins ofparamyxoviruses are important for their pathogenicity (9) . The S1 protein (HA) of reovirus type 3, which specifies a different cell tropism from that of reovirus type 1, is also the major determinant of neurovirulence (10) . The critical role of this viral hemagglutinin in neurovirulence was recently demonstrated by selecting markedly less virulent type 3 variant viruses that are antigenically altered at a site which normally is recognized by monoclonal antibody (11) .
Recently, two nonpathogenic variants ofthe rabies virus CVS strain were detected among several clones resistant to neutralization by monoclonal antibody (12) Fig. 1A shows that all but two of the lysine-containing peaks of the glycoproteins from ERA parent and from ERA RV194-2,C co-elute. The nonmatching peptides, indicated as X and Y in Fig. 1 , are characteristic for the ERA parent and the ERA RV194-2,C, respectively. The separation ofpeptide X observed in Fig. 1A was improved as shown in Fig. 1A Inset by employing a different elution buffer in the reverse-phase HPLC. Cochromatography of lysine-containing peptides of the glycoproteins of the ERA parent and. a revertant of the ERA RV194-2,C exhibited no differences in their elution profiles (Fig. 1B) .
A comparison of lysine-containing tryptic peptides derived from the glycoproteins of CVS parent and CVS RV194-2 also revealed two nonmatching peptides, each specific for either the parent or variant glycoprotein (Fig. 1C) amino acid in the glycoprotein of the rabies antigenic variants by the dideoxy sequencing method (23), using reverse transcriptase to synthesize partial cDNA copies ofthe vRNA gene. The restriction fragment chosen from our cloned ds DNA copy ofthe ERA glycoprotein mRNA sequence allowed us to examine the nucleotide sequence transcribed beyond base 988 of the cloned cDNA. The results obtained when comparing cDNA sequences derived from ERA parental vRNA as template and two ERA variant virus vRNAs (RV194-2,A and RV194-2,B) are shown in Fig. 3A . The sequences were identical to the cloned cDNA sequence (20) except for the appearance of a T at base 1,062 in the two variant virus cDNAs. A G -+ T base change at base 1, 062 indicated that the amino acid corresponding to arginine-333 in the original sequence should be isoleucine in the ERA RV194-2 glycoprotein, confirming the amino acid substitution in ERA peptide Y (Fig. 2) . The appearance ofa G base in the same sequence position suggested that the parental sequence was still present, although the parental phenotype was not expressed.
The nucleotide sequence of the same genomic region of a third nonpathogenic ERA variant, RV194-2,C, was compared with the corresponding sequence of two other ERA variants, RV101-1 and RV110-3, by the same method (Fig. 3B) . The two antigenic variants selected with anti-glycoprotein monoclonal antibodies 101-1 and 110-3 have epitopes residing in antigenic sites II and IV, respectively (see Table 1 ). Again, the only change that was detected in the partial sequence was the G -* T base change in the RV194-2,C cDNA at base 1,062 compared with the other variant sequences and the cloned sequence (20) .
A partial sequence coding for amino acid residues of the parental CVS glycoprotein was compared to the ERA sequence by using the HinfI/EcoRII 62-bp primer from the cloned ERA ds DNA. In Fig. 2 , the predicted amino acid sequence for the CVS strain is compared with that for the ERA strain, for amino acids 330-337. These data have provided the evidence that the amino acid residue in the parental CVS glycoprotein corresponding to residue 333 of the ERA glycoprotein sequence is also arginine.
DISCUSSION
The selection of pathogenic mutants of fixed rabies virus by using neutralizing (anti-glycoprotein) monoclonal antibodies (24) . In addition to RV194-2 viruses, only the attenuated (nonpathogenic for adult mice) Flury HEP (high egg passage) (3) and Kelev (2) strains resist neutralization by these two monoclonal antibodies. However, viruses that have been derived from Flury HEP after one or two passages in suckling mouse brain (12) or in neuroblastoma cells (4) and are pathogenic for adult mice are neutralized by 194-2 and 248-8. Although this reactivity pattern is consistent for the fixed rabies viruses, it does not hold for some street strains. For example, a number ofrabies virus strains isolated from humans, cattle, and dogs in South America and from bats in the United States (25) 
